Navigation Links
Nektar Therapeutics Reports Third Quarter 2010 Financial Results
Date:11/4/2010

as compared to a net loss of $31.0 million or $0.33 per share in the third quarter of 2009.

Conference Call to Discuss Third Quarter 2010 Financial ResultsA conference call to review the financial results will be held today, Thursday, November 4, 2010 at 2 PM Pacific Time.  

Details are below:

The press release and a live audio-only Webcast of the conference call can be accessed through a link that is posted on the home page and Investor Relations section of the Nektar website: http://www.nektar.com. The web broadcast of the conference call will be available for replay through Friday, November 19, 2010. To access the conference call, follow these instructions:Dial: (800) 798-2864 (U.S.); (617) 614-6206 (international)Passcode: 87996589 (Nektar is the host)An audio replay will also be available shortly following the call through Friday, November 19, 2010 and can be accessed by dialing (888) 286-8010 (U.S.); or (617) 801-6888 (international) with a passcode of 55049373.

In the event that any non-GAAP financial measure is discussed on the conference call that is not described in the press release, or explained on the conference call, related information will be made available on the Investor Relations page at the Nektar website as soon as practical after the conclusion of the conference call.

About NektarNektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms. Nektar has a robust R&D pipeline of potentially high-value therapeutics in oncology, pain and other areas. In the area of pain, Nektar has an exclusive worldwide license agreement with AstraZeneca for Nektar's oral NKTR-118 development program to treat opioid-induced constipation and its NKTR-119 development program for the treatment of pain without constipation side effects. The company has additional pain compounds in prec
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Nektar to Announce Financial Results for the Third Quarter of 2010 on Thursday, November 4, 2010, After Close of U.S.-Based Financial Markets
2. Nektar Presents New Preclinical Data on NKTR-181 at Anesthesiology 2010
3. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Senior Vice President and Chief Medical Officer
4. Nektar Presents Data Demonstrating Favorable Oral Bioavailability and Drug-Drug Interaction Profile for NKTR-118
5. Nektar Therapeutics Reports Second Quarter 2009 Financial Results
6. Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)
7. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
8. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
9. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
10. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
11. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 2014  Luoxis Diagnostics, Inc., a subsidiary of ... that its academic collaborators will present several peer-reviewed ... its novel RedoxSYS Diagnostic System, a first-in-class platform ... in response to injury or illness.  A poster ... clinical marker will be presented by Christopher ...
(Date:10/20/2014)... 2014 Valeritas, Inc., a leader in simple, ... Type 2 diabetes, announced today that it has received ... award was presented October 16 th at Cardinal,s ... . The Cardinal Health Supply ... of metrics specifically targeted at the importance of developing ...
(Date:10/20/2014)... DIEGO , Oct. 20, 2014  AnaptysBio, ... of therapeutic antibodies, today announced the appointment of ... Officer. Dr. Londei will lead the preclinical and ... "We are pleased to welcome Dr. ... Hamza Suria , President and Chief Executive Officer ...
Breaking Medicine Technology:Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 2Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 3Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 4Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 5Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 2Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 3AnaptysBio Appoints Dr. Marco Londei to Newly Created Chief Development Officer Position Clinical Immunologist to Lead AnaptysBio's Pipeline Advancement 2
... NEW YORK, March 7, 2011 Reportlinker.com ... is available in its catalogue: ... Future Growth to be Driven by Improving ... http://www.reportlinker.com/p0409144/Aesthetic-Devices-Market-to-2017---Future-Growth-to-be-Driven-by-Improving-Treatment-Outcomes-and-Increase-in-Consumer-Confidence.html ...
... Therapeutics Inc. (TSX: NPC), today announced that their March ... LINK: www.retailinvestorconferences.com Click the red "register/ ... will be available 24/7 for 90 days. Investors may ... the next three weeks. About Allon ...
Cached Medicine Technology:Reportlinker Adds Aesthetic Devices Market to 2017 - Future Growth to be Driven by Improving Treatment Outcomes and Increase in Consumer Confidence 2Reportlinker Adds Aesthetic Devices Market to 2017 - Future Growth to be Driven by Improving Treatment Outcomes and Increase in Consumer Confidence 3Allon Therapeutics' CEO Presentation Now Available for On-Demand Viewing at RetailInvestorConferences.com 2Allon Therapeutics' CEO Presentation Now Available for On-Demand Viewing at RetailInvestorConferences.com 3
(Date:10/20/2014)... With a mere 19 days to November ... brief fundraising stop at the  Law Offices of ... a debate last night with his opponent Gov. Rick ... first seven minutes because Crist had an electric fan ... in one word: "weird." , Before touching on his ...
(Date:10/20/2014)... New York, NY (PRWEB) October 20, 2014 ... City based non-profit organization that helps New Yorkers ... lasting, positive changes toward health, housing, recovery and ... who have transformed the local community through their ... Managing Director, Marc Shapses , has been ...
(Date:10/20/2014)... October 20, 2014 hc1.com today ... secure cloud solution that enables healthcare organizations of ... ultimate healthcare-specific customer relationship management (“CRM”) solution. , ... unique needs of the healthcare industry, the hc1 ... providers and patients by combining healthcare CRM, HIPAA-compliant ...
(Date:10/20/2014)... 20, 2014 My Clients Plus ( ... application. The new module enables easy administration and ... life-cycle quality care. , This application allows users such ... practice, attach a to-do item to a specific client, ... set up reoccurring reminders for follow-ups. It's designed ...
(Date:10/20/2014)... October 20, 2014 Myoderm ... as Assistant Director of their CentralSource ... managing the innovative turnkey drug sourcing, distribution, and ... brings over 12 years of industry experience, in ... at the peak of their international success to ...
Breaking Medicine News(10 mins):Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 2Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 3Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3Health News:Healthcare Relationship Management (HRM) Leader hc1.com® Launches hc1® Quick Start™ 2Health News:My Clients Plus Announces New Workflow Management Software 2Health News:Myoderm Hires Matthew Voicheck to Lead Turnkey Drug Sourcing Service 2
... Eat Right, Move More and ... Milk Their Diets, DENVER, June 5 ... fad diets -- which seem to go in and out of,fashion like shoulder ... remain overweight or obese., A new campaign crossing the country, the Campaign ...
... ATLANTA, June 5 Elekta, a world class ... selected to supply,multiple Elekta Synergy(R) digital linear accelerator ... next few years., The new Elekta Synergy ... Radiation Therapy (IGRT), which Mary Bird Perkins,(MBP) began ...
... Fever for an evening of celebration, INDIANAPOLIS, June 5 ... honored by the March of Dimes on June 7 at ... help families,with critically ill babies throughout the state and to ... For several years, Anthem has teamed up with the March ...
... Coalition warns patients about injections on vacation ... YORK, June 5 The Physicians Coalition,for ... worldwide of the dangers of accepting Botox(R), ... from unfamiliar physicians during,vacation, cruise or spa ...
... watching a small group of neurons that enable sexual maturity ... near the developing nose, to deep inside the brain. ... the zebrafish will help explain why some neurons don,t make ... sexually mature as a result. , "They can go ...
... University researcher Bess Dawson-Hughes, M.D., chaired the ... Foundation (NOF) Clinician,s Guide to Prevention and ... Guide incorporates the World Health Organization (WHO) ... tool expected to increase the identification of ...
Cached Medicine News:Health News:Message to Denver Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 2Health News:Message to Denver Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 3Health News:Message to Denver Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 4Health News:Elekta and Mary Bird Perkins Cancer Center Sign Strategic Multi-Center Radiation Therapy Systems Agreement 2Health News:Elekta and Mary Bird Perkins Cancer Center Sign Strategic Multi-Center Radiation Therapy Systems Agreement 3Health News:Anthem Blue Cross and Blue Shield Honored by March of Dimes 2Health News:Botox and Restylane Not A Destination or Spa Treatment 2Health News:Botox and Restylane Not A Destination or Spa Treatment 3Health News:Botox and Restylane Not A Destination or Spa Treatment 4Health News:Zebrafish enable scientists to study the migration of neurons that enable sexual maturity 2Health News:Zebrafish enable scientists to study the migration of neurons that enable sexual maturity 3Health News:Tufts researcher leads revision of osteoporosis guidelines 2Health News:Tufts researcher leads revision of osteoporosis guidelines 3